Syncom Formulations (India) share price & results
- Jun 2026
- Sept 2026
Indore-based pharma maker of generic formulations, nutraceuticals and injectables, manufactured at its Pithampur plant.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 126 | +7.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 21.0 | +7.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 25.0 | +56.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 22.72 | +2.2 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 9.43 | +6.6 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 0.40 | −71.3 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance +23.6% 1Y
1Y: ₹16.67 on 24 Oct 2025 → ₹20.61. High ₹26.18 (29 Sept 2026), low ₹10.3 (30 Mar 2026).
- Previous close
- ₹20.05
- Market cap
- ₹2.0k Cr
- 52-week range
- ₹10.3 – ₹26.18
- One year
- +24.23%
- Price to earnings (TTM to Jun 2026)
- 23.16×
- Return on equity (TTM to Jun 2026)
- 22.72%
Overview
- Symbol
- NSE:SYNCOMF
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Syncom Formulations (India) Limited does
Based on the company's own presentations, annual report and earnings calls.
Syncom Formulations (India) Limited manufactures and markets pharmaceutical products, earning revenue from sale of generic formulations, nutraceuticals and injectables to domestic and international markets. Manufacturing is carried out at its works in Pithampur, Dhar district (Madhya Pradesh), with corporate functions run out of Indore. The company sells across semi-urban and rural markets in India alongside an export business that it has been expanding into new geographies through additional product registrations.
- Manufacturing facility
- Works/plant at Pithampur, Dhar (Madhya Pradesh)
- Corporate office
- Indore, Madhya Pradesh
- Product portfolio breadth
- Generic formulations, nutraceuticals and injectables
- Market presence
- Domestic sales (incl. semi-urban and rural markets) plus exports to international markets
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2017 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +56% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 102 | 128 | 149 | 117 | 122 | 115 | 135 | 126 |
| Expenses | 90 | 113 | 131 | 101 | 103 | 94 | 113 | 99 |
| Operating profit | 12 | 15 | 18 | 16 | 18 | 21 | 22 | 26 |
| Operating margin | 12.0% | 12.0% | 12.0% | 14.0% | 15.0% | 18.0% | 16.0% | 21.0% |
| Other income | 4 | 4 | 7 | 6 | 5 | 6 | 15 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | 15 | 17 | 23 | 20 | 22 | 25 | 34 | 32 |
| Tax rate | 25.0% | 25.0% | 24.0% | 22.0% | 25.0% | 25.0% | 25.0% | 23.0% |
| Net profit | 11 | 13 | 18 | 16 | 17 | 19 | 25 | 25 |
| EPS (₹ per share) | 0.12 | 0.14 | 0.19 | 0.17 | 0.18 | 0.20 | 0.27 | 0.26 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 223 | 264 | 466 | 489 |
| Expenses | 204 | 233 | 411 | 411 |
| Operating profit | 19 | 28 | 55 | 77 |
| Other income | 15 | 14 | 16 | 32 |
| Interest | 3 | 4 | 0 | 0 |
| Depreciation | 4 | 4 | 4 | 5 |
| Profit before tax | 26 | 33 | 65 | 101 |
| Net profit | 20 | 25 | 50 | 77 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 86 | 94 | 94 | 94 | 94 | 94 |
| Reserves | 136 | 162 | 194 | 248 | 282 | 321 |
| Borrowings | 58 | 83 | 72 | 5 | 0 | 1 |
| Other liabilities | 28 | 39 | 44 | 67 | 74 | 117 |
| Total liabilities | 308 | 378 | 405 | 413 | 451 | 534 |
| Fixed assets | 94 | 91 | 120 | 125 | 124 | 184 |
| Capital work in progress | 6 | 26 | 0 | 0 | 8 | 0 |
| Investments | 43 | 64 | 66 | 93 | 148 | 109 |
| Other assets | 165 | 197 | 219 | 196 | 171 | 241 |
| Total assets | 308 | 378 | 405 | 413 | 451 | 534 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | -2 | 16 | 11 | -6 | 23 | 58 |
| Cash from investing | -75 | -27 | -45 | 83 | -18 | -51 |
| Cash from financing | 72 | 8 | 35 | -15 | -68 | -3 |
| Net cash flow | -5 | -2 | 1 | 62 | -63 | 4 |
| Free cash flow | -5 | 5 | -10 | -14 | 13 | 46 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 112 | 114 | 124 | 144 | 85 | 83 |
| Inventory days | 51 | 51 | 55 | 49 | 49 | 81 |
| Days payable | 66 | 36 | 53 | 56 | 52 | 96 |
| Cash conversion cycle | 96 | 129 | 126 | 137 | 82 | 68 |
| Working capital days | 28 | 33 | -4 | 51 | 95 | 85 |
| Return on capital employed | 21.0% | — | 10.0% | 11.0% | 19.0% | 25.0% |
| Dividend payout | 0.0% | 13.0% | 0.0% | 0.0% | 0.0% | 12.0% |
Where revenue comes from
The businesses behind the company’s reported revenue.
Pharmaceuticals Drugs & formulations contributes 99.2% of reported segment revenue.
Quarter ended 30 Jun 2026 · Consolidated
- Pharmaceuticals Drugs & formulations 99.2%
₹132.24 crore
- Renting of Property 0.6%
₹0.84 crore
- Trading of Commodities 0.2%
₹0.28 crore
| Business segment | Revenue · ₹ crore | Share |
|---|---|---|
| Pharmaceuticals Drugs & formulations | 132.24 | 99.2% |
| Renting of Property | 0.84 | 0.6% |
| Trading of Commodities | 0.28 | 0.2% |
Share = segment revenue ÷ total segment revenue, before intersegment adjustments.
How these numbers add up
- Total segment revenue
- ₹133.36 crore
- Intersegment adjustment
- ₹0.00 crore
- Net segment revenue
- ₹133.36 crore
Intersegment transactions are between the company’s own businesses. Net segment revenue can differ from income-statement revenue because reporting definitions differ.
Source: FinEdge · Last checked 19 Sept 2026. Reported segment names are kept as supplied.
How the mix has moved
Trading of Commodities shrank from 1% to 0% of revenue over the last two years.
| Segment | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Pharmaceuticals Drugs & formulations | — | — | — | — | — | — | — | 99% | — |
| Renting of Property | 1% | 1% | — | — | 1% | — | 1% | 1% | — |
| Trading of Commodities | 1% | 2% | — | 1% | 0% | — | <1% | <1% | -73.4% |
Share of reported segment revenue by quarter, consolidated basis, as filed. A quarter the company did not report is left blank, never carried forward.
See how segments are shifting across companies → Segment Shift
What the price assumes
AttractiveTo justify its price of ₹21, this stock must grow earnings at 20% every year for 7 years. Our analysis caps realistic growth at ~49%. At that growth it is worth ₹84 — upside of 307%.
- Growth the price implies
- 20.1% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 48.9% a year
- net profit, FY23–FY26 · EPS 49.5%
- The gap
- -0.3 pp
- 307% downside if it only repeats history
Ownership
Who owns it
Promoters hold 50.57% as of Sept 2026; institutions added 1.88 pts since Jun 2026.
- Promoters 50.57%
- Foreign institutions 2.23%
- Domestic institutions 0.00%
- Public 47.20%
Who is on the register
Named in the Sep 2026 filing
Every holder of Syncom Formulations (India) Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 12.44% | unchanged | |
| 10.48% | unchanged | |
| 5.02% | unchanged | |
| 4.99% | unchanged | |
| 4.90% | unchanged | |
| 4.26% | unchanged | |
| 3.82% | unchanged | |
| 1.28% | unchanged | |
| 1.25% | unchanged | |
| 1.12% | unchanged | |
| 0.99% | unchanged | |
| 0.02% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Syncom Formulations (India) Limited
Free account: one company. Everything above stays public.
Write why you follow Syncom Formulations (India) Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Syncom Formulations (India) Limited
Guides on how to read this kind of business and the numbers that matter.